Premium
Bcl‐2 proto‐oncogene expression in low‐ and high‐grade prostatic intraepithelial neoplasia
Author(s) -
Baltaci S.,
Orhan D.,
Özer G.,
Tolunay Ö.,
Gög?üs O.
Publication year - 2000
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1046/j.1464-410x.2000.00388.x
Subject(s) - immunostaining , intraepithelial neoplasia , high grade prostatic intraepithelial neoplasia , pathology , staining , immunohistochemistry , prostate , carcinogenesis , oncogene , hyperplasia , adenocarcinoma , basal (medicine) , biology , medicine , cancer , cell cycle , insulin
Objective To determine the incidence of bcl‐2 protein expression in low‐ and high‐grade prostatic intra‐epithelial neoplasia (PIN) lesions, and to explore the role of bcl‐2 in prostatic tumorigenesis. Materials and methods Immunoreactivity for bcl‐2 was examined in 10 samples of benign prostatic hyperplasia (BPH), 13 of primary prostatic adenocarcinoma, 15 of high‐grade PIN and 18 of low‐grade PIN. All immunostaining results were scored for the approximate percentage of positive tumour cells and relative immunostaining intensity (score range 0–12). Results In all BPH samples, bcl‐2 staining was detected consistently in the basal cell layer of the ducts and acini, but no staining was ever apparent in luminal cells. The immunoreactivity for bcl‐2 was heterogeneous in the prostatic carcinomas and bcl‐2 protein expression was present in six samples. In these six bcl‐2‐positive tumours, the mean (range) staining score was 1.15 (1–6). There was detectable expression of bcl‐2 in low‐ and high‐grade PIN in all cell layers; immunoreactivity was present in 10 of 15 high‐grade PIN lesions, with a mean (range) score of 1.14 (1–4), and in 12 of 18 samples of low‐grade PIN, with a mean (range) score of 1.77 (1–6). Conclusions The high incidence of bcl‐2 protein expression in low‐ and high‐grade PIN lesions suggests that bcl‐2 protein expression is associated with early prostate tumorigenesis.